Prediabetes: Risk factors instead of complaints?
https://doi.org/10.62751/2713-0177-2025-6-1-07
Abstract
Prediabetes is a clinical condition characterized by impaired glucose tolerance, insulin resistance, and an increased risk of developing type 2 diabetes mellitus. In addition to its progression to diabetes, prediabetes is an independent risk factor for cardiovascular diseases (CVD) due to a complex of pathophysiological mechanisms, including endothelial dysfunction, chronic inflammation, and lipid metabolism disorders. Moreover, the presence of CVD itself can contribute to worsening insulin sensitivity, thereby increasing the likelihood of developing prediabetes. This article presents current data on the epidemiology, pathogenesis, diagnostic methods, and pharmacotherapy of prediabetes, along with a comparative analysis of pharmacological approaches, including Subetta®, metformin and GLP-1 receptor agonists.
About the Authors
I. A. Barsukov
Moscow Regional Research and Clinical Institute; JSC MEDSI Group of Companies
Russian Federation
Russian Federation
Ilya A. Barsukov – MD, PhD, senior researcher at the Department of therapeutic endocrinology of Moscow Regional Research and Clinical Institute; chief specialist in the field of endocrinology of the network of JSC MEDSI Group of Companies
Scopus Author ID: 57225446501
Moscow
A. A. Demina
Moscow Regional Research and Clinical Institute
Russian Federation
Russian Federation
Anna A. Demina – MD, researcher at the Department of therapeutic endocrinology
Scopus Author ID: 58318134200
Moscow
References
1. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2023; 26(2S): 1–231. doi:10.14341/DM13042.
2. Чазова И.Е., Шестакова М.В., Жернакова Ю.В. с соавт. Евразийские рекомендации по профилактике и лечению сердечно-сосудистых заболеваний у больных с диабетом и предиабетом. Евразийский кардиологический журнал. 2021; (2): 6–61. doi: 10.38109/2225-1685-2021-2-6-61.
3. Шестакова Е.А., Лунина Е.Ю., Галстян Г.Р. с соавт. Распространенность нарушений углеводного обмена у лиц с различными сочетаниями факторов риска сахарного диабета 2 типа в когорте пациентов исследования NATION. Сахарный диабет. 2020; 23(1): 4–11. doi: 10.14341/DM12286.
4. Мкртумян А. М. Сравнительный анализ эффективности препаратов для лечения ранних нарушений углеводного обмена. Терапевтический архив. 2024; 96(4): 419–428. doi: 10.26442/00403660.2024.04.202709.
5. Chianelli M, Armellini M, Carpentieri M et al. Obesity in prediabetic patients: Management of metabolic complications and strategies for prevention of overt diabetes. Endocr Metab Immune Disord Drug Targets. 2025; 25(1): 8–36. doi: 10.2174/0118715303282327240507184902.
6. Nanavaty D, Green R, Sanghvi A et al. Prediabetes is an incremental risk factor for adverse cardiac events: A nationwide analysis. Atheroscler Plus. 2023; 54: 22–26. doi: 10.1016/j.athplu.2023.08.002.
7. Huang Y, Cai X, Mai W et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis. BMJ. 2016; 355: i5953. doi: 10.1136/bmj.i5953.
8. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease. J Am Coll Cardiol. 2010; 55(13): 1310–17. doi: 10.1016/j.jacc.2009.10.060
9. Perreault L, Pan Q, Mather KJ et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: Results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012; 379(9833): 2243–51. doi: 10.1016/S0140-6736(12)60525-X.
10. Yudkin JS, Montori VM. The epidemic of pre-diabetes: The medicine and the politics. BMJ. 2014; 349: g4485. doi: 10.1136/bmj.g4485.
11. Cai X, Zhang Y, Li M et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: Updated meta-analysis. BMJ. 2020: 370: m2297. doi: 10.1136/bmj.m2297.
12. ElSayed NA, Aleppo G, Aroda VR et al. 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes – 2023. Diabetes Care. 2023; 46(Suppl_1): S19– S40. doi: 10.2337/dc23-S002.
13. Liu C, Foti K, Grams ME et al. Trends in self-reported prediabetes and metformin use in the USA: NHANES 2005–2014. J Gen Intern Med. 2020; 35(1): 95–101. doi: 10.1007/s11606-019-05398-5.
14. Neves JS, Newman C, Bostrom JA et al. Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Res Clin Pract. 2022; 190: 109980. doi:10.1016/j.diabres.2022.109980.
15. Silveira THR, Silva FH, Hill WG et al. Targeting NADPH oxidase as an approach for diabetic bladder dysfunction. Antioxidants. 2024; 13(10): 1155. doi:10.3390/antiox13101155.
16. Hill MA, Yang Y, Zhang L et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021; 119: 154766. doi:10.1016/j.metabol.2021.154766.
17. Kong P, Cui ZY, Huang XF et al. Inflammation and atherosclerosis: Signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022; 7(1): 131. doi:10.1038/s41392-022-00955-7.
18. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018; 17(1): 121. doi:10.1186/s12933-018-0763-3.
19. Li X, Weber NC, Cohn DM, et al. Effects of hyperglycemia and diabetes mellitus on coagulation and hemostasis. J Clin Med. 2021; 10(11): 2419. doi:10.3390/jcm10112419.
20. Marx N, Federici M, Schütt K et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043–140. doi: 10.1093/eurheartj/ehad192.
21. Cesaro A, De Michele G, Fimiani F et al. Visceral adipose tissue and residual cardiovascular risk: A pathological link and new therapeutic options. Front Cardiovasc Med. 2023; 10: 1187735. doi: 10.3389/fcvm.2023.1187735.
22. Einarson TR, Acs A, Ludwig C, Panton UH. Economic burden of cardiovascular disease in type 2 diabetes: A systematic review. Value Health. 2018; 21(7): 881–90. doi: 10.1016/j.jval.2017.12.019.
23. Inciardi RM, Claggett B, Gupta DK et al. Cardiac structure and function and diabetes‐related risk of death or heart failure in older adults. J Am Heart Assoc. 2022; 1(6): e022308. doi:10.1161/JAHA.121.022308.
24. Trujillo-Garrido N, Santi-Cano MJ. Motivation and limiting factors for adherence to weight loss interventions among patients with obesity in primary care. Nutrients. 2022; 14(14): 2928. doi: 10.3390/nu14142928.
25. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393–403. doi:10.1056/NEJMoa012512.
26. Общая характеристика лекарственного препарата Субетта® [Электронный ресурс]. Портал Евразийского экономического союза. Доступ: https://portal.eaeunion.org/sites/commonprocesses/ru-ru/Pages/CardView.aspx?documentId=675a989930dcf8c882a545ec&codeId=P.MM.01 (дата обращения – 09.03.2025)
27. Mkrtumyan A, Ametov A, Demidova T et al. A new approach to overcome insulin resistance in patients with impaired glucose tolerance: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial of efficacy and safety of Subetta. J Clin Med. 2022; 11(5): 1390. doi:10.3390/jcm11051390.
28. Мкртумян А.М., Воробьев С.В., Волкова А.Р., Ворохобина Н.В. Влияние препарата Субетта на гликемический контроль у пациентов с сахарным диабетом 2 типа: результаты многоцентрового двойного слепого плацебоконтролируемого рандомизированного клинического исследования. Фарматека. 2020; 27(12): 38–48. doi: 10.18565/pharmateca.2020.12.38-48.
29. Шинкин М.В., Звенигородская Л.А., Мкртумян А.М. Использование лазерной допплеровской флоуметрии и флуоресцентной спектроскопии для оценки состояния микроциркуляторного русла и тканевого метаболизма у больных сахарным диабетом 2 типа на фоне терапии препаратом Субетта. Эффективная фармакотерапия. 2020; 16(12): 8–14. doi:10.33978/2307-3586-2020-16-12-8-14.
30. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834–44. doi: 10.1056/NEJMoa1607141.
Supplementary files
Review
For citations:
Barsukov I.A., Demina A.A. Prediabetes: Risk factors instead of complaints? FOCUS. Endocrinology. 2025;6(1):52-57. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-1-07
Views:
45
Email this article 